117 related articles for article (PubMed ID: 25450687)
1. Atypical nuclear localization of VIP receptors in glioma cell lines and patients.
Barbarin A; Séité P; Godet J; Bensalma S; Muller JM; Chadéneau C
Biochem Biophys Res Commun; 2014 Nov; 454(4):524-30. PubMed ID: 25450687
[TBL] [Abstract][Full Text] [Related]
2. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer.
Valdehita A; Bajo AM; Fernández-Martínez AB; Arenas MI; Vacas E; Valenzuela P; Ruíz-Villaespesa A; Prieto JC; Carmena MJ
Peptides; 2010 Nov; 31(11):2035-45. PubMed ID: 20691743
[TBL] [Abstract][Full Text] [Related]
3. Alterations in the relative abundance of the vasoactive intestinal peptide receptors (VPAC1 and VPAC2) and functions in uterine contractility during inflammation.
Palus K; Całka J; Jana B
Anim Reprod Sci; 2021 Feb; 225():106680. PubMed ID: 33388613
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.
Fernández-Martínez AB; Carmena MJ; Arenas MI; Bajo AM; Prieto JC; Sánchez-Chapado M
Histol Histopathol; 2012 Aug; 27(8):1093-101. PubMed ID: 22763881
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
6. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
7. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
Yadav M; Huang MC; Goetzl EJ
Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide and its receptors in human ovarian cortical follicles.
Gabbay-Benziv R; Ao A; Fisch B; Zhang L; Oron G; Kessler-Icekson G; Ben-Haroush A; Krissi H; Abir R
PLoS One; 2012; 7(5):e37015. PubMed ID: 22623971
[TBL] [Abstract][Full Text] [Related]
9. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
10. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
[TBL] [Abstract][Full Text] [Related]
11. VPAC
Cunha-Reis D; Ribeiro JA; de Almeida RFM; Sebastião AM
Br J Pharmacol; 2017 Dec; 174(24):4725-4737. PubMed ID: 28945273
[TBL] [Abstract][Full Text] [Related]
12. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
13. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells.
Lara-Marquez M; O'Dorisio M; O'Dorisio T; Shah M; Karacay B
J Immunol; 2001 Feb; 166(4):2522-30. PubMed ID: 11160313
[TBL] [Abstract][Full Text] [Related]
14. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
Juarranz Y; Gutiérrez-Cañas I; Santiago B; Carrión M; Pablos JL; Gomariz RP
Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383
[TBL] [Abstract][Full Text] [Related]
16. Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.
Cunha-Reis D; Aidil-Carvalho Mde F; Ribeiro JA
Hippocampus; 2014 Nov; 24(11):1353-63. PubMed ID: 24935659
[TBL] [Abstract][Full Text] [Related]
17. Gene expression of vasoactive intestinal peptide receptors in human lung cancer.
Szilasi M; Buglyo A; Treszl A; Kiss L; Schally AV; Halmos G
Int J Oncol; 2011 Oct; 39(4):1019-24. PubMed ID: 21769421
[TBL] [Abstract][Full Text] [Related]
18. Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.
Vomhof-DeKrey EE; Sandy AR; Failing JJ; Hermann RJ; Hoselton SA; Schuh JM; Weldon AJ; Payne KJ; Dorsam GP
Peptides; 2011 Oct; 32(10):2058-66. PubMed ID: 21878358
[TBL] [Abstract][Full Text] [Related]
19. Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide.
Fabricius D; O'Dorisio MS; Blackwell S; Jahrsdörfer B
J Immunol; 2006 Nov; 177(9):5920-7. PubMed ID: 17056516
[TBL] [Abstract][Full Text] [Related]
20. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]